Publications by authors named "N Kanaya"
Objective: Trifluridine/tipiracil (FTD/TPI) is one of the options for late-line treatment of colorectal cancer (CRC). However, the specific patient populations that would particularly benefit from it remain unclear. This study attempted to identify predictive markers of chemotherapy efficacy with trifluridine/tipiracil (FTD/TPI), focusing on the RNA-editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) expression and neutrophil-lymphocyte ratio (NLR).
View Article and Find Full Text PDFPurpose: Gastric cancer (GC) remains a major malignancy. Robotic gastrectomy (RG) has gained popularity due to various advantages. Despite those advantages, many hospitals lack the necessary equipment for RG and are still performing laparoscopic gastrectomy (LG) due to its established minimal invasiveness and safety.
View Article and Find Full Text PDFWork-life balance is often discussed in Japan. Yet surgeons find it challenging to take paternity leave because of their demanding surgical duties and a strong sense of responsibility. One Japanese male surgeon had his first paternity experience as a research fellow in the US.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on the relationship between preoperative nutritional status and outcomes in colorectal cancer patients aged 75 and older, evaluating 71 patients who underwent surgery from July 2020 to September 2022.
- Patients were categorized using the Subjective Global Assessment (SGA) into well-nourished and varying levels of malnourished groups, finding correlations between nutritional status and postoperative results.
- The results indicated that malnourished patients (SGA-B/C) had higher ICU admissions, longer hospital stays, and significantly lower 3-year overall survival rates compared to well-nourished patients (SGA-A), highlighting the importance of assessing nutrition in older surgical patients.
Recent progress in cancer cell-based therapies has led to effective targeting and robust immune responses against cancer. However, the inherent safety risks of using live cancer cells necessitate the creation of an optimized safety switch without hindering the efficacy of immunotherapy. The existing safety switches typically induce tolerogenic cell death, potentially leading to an immunosuppressive tumor immune microenvironment (TIME), which is counterproductive to the goals of immunotherapy.
View Article and Find Full Text PDF